https://orcid.org/0000-0002-6562-0767
Key Points
Clonal relatedness of RT-DLBCL to underlying CLL has been shown to confer poor prognosis in a modest number of cohort studies.
Clonally-related RT-DLBCL typically occurs alongside other poor risk features with limited current evidence for independent significance.
Disease shift of chronic lymphocytic leukemia (CLL) to diffuse large B-cell lymphoma (DLBCL), so-called Richter transformation (RT), is a catastrophic clinical event. Rarely survival can outperform expectations and accurate prognostication for patients may affect therapeutic choices. To date, prognosis has relied on readily available factors such as TP53 disruption, prior CLL treatment status and performance score. Recently, shared clonality assessment by immunoglobulin heavy-chain variable (IgHV) region sequencing of the CLL and RT has been considered therapeutically relevant, but this is infrequently performed. We performed a systematic review of peer-reviewed manuscripts where outcomes in relation to clonal relatedness and lack thereof (clonally-related and -unrelated RT-DLBCL) were examined. Fifteen manuscripts which included 336 patients were found, of which six compared survival outcomes between the two groups in a statistically meaningful way. Two analyses showed no difference in survival outcomes with four studies reporting a significantly poorer prognosis with clonally-related RT-DLBCL. In two of these studies the baseline characteristics of clonally-related and -unrelated groups were compared and the clonally-related cases were enriched for underlying CLL which was TP53 disrupted, IgHV unmutated, more heavily pretreated and exhibiting stereotyped B-cell receptor VH CDR3, as well as RT-DLBCL which was MYD88wt. We demonstrate that although clonal relatedness of the underlying CLL confers a poorer survival, this is not demonstrated in any study to be independent of other well-described clinical and genomic variables known to influence outcome in RT-DLBCL. Further independent validation of this prognostic factor is required to help guide universal adoption into clinical practice.
